290 related articles for article (PubMed ID: 36057834)
1. GBA1 and The Immune System: A Potential Role in Parkinson's Disease?
Al-Azzawi ZAM; Arfaie S; Gan-Or Z
J Parkinsons Dis; 2022; 12(s1):S53-S64. PubMed ID: 36057834
[TBL] [Abstract][Full Text] [Related]
2. Classification of GBA1 Variants in Parkinson's Disease: The GBA1-PD Browser.
Parlar SC; Grenn FP; Kim JJ; Baluwendraat C; Gan-Or Z
Mov Disord; 2023 Mar; 38(3):489-495. PubMed ID: 36598340
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
Lee CY; Menozzi E; Chau KY; Schapira AHV
J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
[TBL] [Abstract][Full Text] [Related]
4. Imaging and genetics in Parkinson's disease: assessment of the GBA1 mutation.
Ghatti S; Yoon E; Lopez G; Ehrlich D; Horovitz SG
J Neurol; 2022 Oct; 269(10):5347-5355. PubMed ID: 35604467
[TBL] [Abstract][Full Text] [Related]
5. Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.
Sanyal A; DeAndrade MP; Novis HS; Lin S; Chang J; Lengacher N; Tomlinson JJ; Tansey MG; LaVoie MJ
Mov Disord; 2020 May; 35(5):760-773. PubMed ID: 32034799
[TBL] [Abstract][Full Text] [Related]
6. Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
Blauwendraat C; Tayebi N; Woo EG; Lopez G; Fierro L; Toffoli M; Limbachiya N; Hughes D; Pitz V; Patel D; Vitale D; Koretsky MJ; Hernandez D; Real R; Alcalay RN; Nalls MA; Morris HR; Schapira AHV; Balwani M; Sidransky E
Mov Disord; 2023 May; 38(5):899-903. PubMed ID: 36869417
[TBL] [Abstract][Full Text] [Related]
7. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
9. Impact of
Stoker TB; Camacho M; Winder-Rhodes S; Liu G; Scherzer CR; Foltynie T; Evans J; Breen DP; Barker RA; Williams-Gray CH
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):695-702. PubMed ID: 32303560
[TBL] [Abstract][Full Text] [Related]
10. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
11. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
12. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
13. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease.
Duran R; Mencacci NE; Angeli AV; Shoai M; Deas E; Houlden H; Mehta A; Hughes D; Cox TM; Deegan P; Schapira AH; Lees AJ; Limousin P; Jarman PR; Bhatia KP; Wood NW; Hardy J; Foltynie T
Mov Disord; 2013 Feb; 28(2):232-236. PubMed ID: 23225227
[TBL] [Abstract][Full Text] [Related]
14. Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
Surface M; Balwani M; Waters C; Haimovich A; Gan-Or Z; Marder KS; Hsieh T; Song L; Padmanabhan S; Hsieh F; Merchant KM; Alcalay RN
Mov Disord; 2022 Feb; 37(2):416-421. PubMed ID: 34741486
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
[TBL] [Abstract][Full Text] [Related]
16. GBA1-and LRRK2-directed Treatments: The Way Forward.
Maayan Eshed G; Alcalay RN
Parkinsonism Relat Disord; 2024 May; 122():106039. PubMed ID: 38438297
[TBL] [Abstract][Full Text] [Related]
17. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
García-Sanz P; Orgaz L; Bueno-Gil G; Espadas I; Rodríguez-Traver E; Kulisevsky J; Gutierrez A; Dávila JC; González-Polo RA; Fuentes JM; Mir P; Vicario C; Moratalla R
Mov Disord; 2017 Oct; 32(10):1409-1422. PubMed ID: 28779532
[TBL] [Abstract][Full Text] [Related]
18. A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.
den Heijer JM; Cullen VC; Quadri M; Schmitz A; Hilt DC; Lansbury P; Berendse HW; van de Berg WDJ; de Bie RMA; Boertien JM; Boon AJW; Contarino MF; van Hilten JJ; Hoff JI; van Mierlo T; Munts AG; van der Plas AA; Ponsen MM; Baas F; Majoor-Krakauer D; Bonifati V; van Laar T; Groeneveld GJ
Mov Disord; 2020 Sep; 35(9):1667-1674. PubMed ID: 32618053
[TBL] [Abstract][Full Text] [Related]
19. Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?
Farfel-Becker T; Do J; Tayebi N; Sidransky E
Trends Neurosci; 2019 Sep; 42(9):631-643. PubMed ID: 31288942
[TBL] [Abstract][Full Text] [Related]
20. The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers.
Toffoli M; Smith L; Schapira AHV
J Neurochem; 2020 Jul; 154(1):11-24. PubMed ID: 31965564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
